The Hidden Cost of Unmanaged GLP-1 Use

Metriana Editorial · May 5, 2026 · 12 min read

Every benefits leader has seen the pharmacy bill. GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) now exceed $1,000 per patient per month before rebates, and they've become one of the fastest-growing cost drivers in employer-sponsored health plans. For many organizations, they've become the most discussed line item in the benefits budget.

The conversation about GLP-1 cost almost always focuses on the wrong number. Most employers are watching what they spend on the drugs. Far fewer are tracking what they're losing from the way those drugs are, or aren't, being managed. That gap between spend and value is where the real cost problem lives.

The pharmacy line isn't the whole bill

The drug cost is only the beginning. For every dollar spent on a GLP-1 prescription, there are downstream costs that don't show up on the pharmacy report. Those costs quietly erode any potential return on the investment.

They fall into four categories:

1. Side-effect management, unattributed medical claims from GI complications.
2. Adherence failure, where most patients stop before the drug works.
3. The regain cycle, paying twice for results that don't last.
4. Compounding risks, adverse events from unmonitored access.

Cost category 1: side-effect management

What does unmanaged GLP-1 use cost in medical claims?

GLP-1 medications work on the gastrointestinal system, and they do so dramatically. Nausea, vomiting, diarrhea, and constipation are among the most common effects. Research shows they affect a substantial portion of early users: approximately 50% to 60% of patients experience gastrointestinal disturbances during the initial treatment phase.

A large-scale study from the Blue Cross Blue Shield Association and Blue Health Intelligence, which compared over one million GLP-1 users to matched non-users, found that persistence on GLP-1 treatment correlated with a meaningful increase in gastrointestinal side effects requiring additional treatment.¹ Among GLP-1 users, GERD (chronic acid reflux) occurred at a rate 5.8 percentage points higher than in non-users.

The FDA has also issued safety warnings around more serious gastrointestinal events. A September 2023 communication flagged the risk of ileus (intestinal obstruction) in GLP-1 patients, and research using the FDA's Adverse Event Reporting System has documented a wide range of GI adverse events in real-world GLP-1 use.²

Without active clinical support to manage these effects (titration guidance, nutrition coaching, monitoring), many patients turn to urgent care or emergency services. That spend lands on the medical side of the ledger, separate from pharmacy, and it rarely gets attributed to GLP-1 use in benefits cost reporting.

Employer blind spot: GI-related urgent care visits among employees on GLP-1s are rarely connected to the drug in benefits cost reporting. The pharmacy cost and the medical cost look like separate line items. The full picture isn't visible.

Cost category 2: the adherence collapse

What percentage of employees stop taking GLP-1 medications before they work?

This is the central economic problem with GLP-1 medications as currently deployed: most people stop taking them before they produce meaningful benefit.

The research on adherence is stark:

• 30% of patients stop within the first 30 days (Blue Health Intelligence).
• 50% have discontinued within 12 months (Evernorth Research Institute).
• Only 14% of patients initiating Wegovy remain on the medication after three years (Prime Therapeutics pharmacy claims analysis).

The Blue Cross Blue Shield Association found that nearly two-thirds of patients discontinue before reaching the 12-week mark generally considered necessary for meaningful weight loss.

For employers, this means a significant share of GLP-1 spend is paying for one to two months of high-cost medication with little to no clinical benefit to show for it. The drug never gets the chance to work.

What is the ROI on GLP-1 medications for employers?

Cigna's member outcomes data tells the return-on-investment story clearly: members who stayed on GLP-1 therapy for at least 12 months saw over $1,100 in reduced medical spend in months 19 through 24, driven by reductions in cardiovascular events, hospitalizations, and comorbidity treatment costs. Aon data shows that the first year of GLP-1 use is typically associated with increased employer healthcare costs, driven by more doctor visits and management of side effects. The investment only starts paying back in year two and beyond, for the patients who stay on the medication with proper support.

Benefits ROI models that evaluate GLP-1 spend on short timelines are structurally set up to show a loss, because they're measuring the cost period without reaching the return period.

Employer blind spot: Without adherence support, employers consistently pay the cost of GLP-1 therapy and rarely reach the savings. The program only pays when patients persist. Most don't.

Cost category 3: the regain cycle, paying twice for nothing

Does weight come back after stopping GLP-1 medications?

Yes, and faster than most programs anticipate.

A systematic review and meta-analysis published in the BMJ (January 2026) found that patients regain weight at an average rate of 0.4 kilograms per month after stopping GLP-1 treatment.³ Body weight and cardiometabolic risk markers are projected to return to pre-treatment levels within 1.4 to 1.7 years. The rate of weight regain after stopping GLP-1 medications is nearly four times faster than after behavioral weight management programs alone.

Clinical trial data is equally clear:

• STEP-1 extension: Two-thirds of weight lost on semaglutide returned within 12 months of discontinuation.⁴
• SURMOUNT-4 trial: More than 50% of weight loss with tirzepatide rebounded over 52 weeks of discontinuation.

Does cardiovascular risk return after stopping GLP-1 medications?

It does, and a major 2026 study quantifies the risk in terms employers and clinicians need to understand.

Washington University School of Medicine researchers, publishing in BMJ Medicine in March 2026, followed more than 333,000 veterans with type 2 diabetes over three years.⁵ They found that stopping or interrupting GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events. After two years off GLP-1 medication, the increased risk of heart attack, stroke, and death reached as high as 22%, largely erasing the cardiovascular benefits earned during treatment.

The lead researcher summarized the finding directly: "There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop."

What is the GLP-1 restart cycle, and what does it cost employers?

When patients stop GLP-1 medications and regain weight, the clinical and financial pattern is predictable: comorbidities reassert, and many patients (or their physicians) decide to restart the medication. Research documents that patients who regained weight after GLP-1 discontinuation were more likely to reinitiate the medications. Each restart costs the same as the first prescription.

From the claims perspective, this cycle looks like new GLP-1 utilization. It isn't. It's the same spend, recycled, producing the same temporary results, because the underlying behavioral and clinical conditions that drive regain were never addressed.

Employer blind spot: The regain cycle creates compounding costs with no net clinical gain. Without behavioral infrastructure built during the medication window, every treatment episode is a temporary result, not a durable one.

Cost category 4: the compounding problem

What are the risks of compounded GLP-1 medications for employers?

Not all GLP-1 use is flowing through employer health plans.

The shortage of brand-name GLP-1 medications over the past two years created a market for compounded semaglutide, unregulated versions produced by compounding pharmacies and distributed largely through telehealth platforms. Compounded medications were legally permitted during periods of FDA-declared drug shortage, but those shortages have since ended, and the FDA moved to restrict compounded GLP-1 production beginning in 2025.

The risks were not theoretical. U.S. poison control centers reported a spike in medical issues linked to compounded GLP-1 products, and the FDA issued a warning about a surge in overdoses and adverse events, many attributed to dosing errors in compounded formulations. By mid-2025, more than 1,000 adverse events linked to compounded GLP-1 products had been reported.

From the employer perspective, two dimensions of risk matter:

First, employees who access compounded GLP-1s through direct-to-consumer telehealth services may experience adverse events that land in the employer's medical claims, regardless of whether the employer's benefit plan covered the medication.

Second, employees accessing GLP-1s through unregulated channels are almost certainly doing so without clinical oversight, monitoring, or behavioral support, amplifying every cost category described above.

Employer blind spot: Benefit coverage decisions do not determine GLP-1 access. Employees are obtaining these medications independently, and the adverse event costs still hit the group health plan.

What this means for employers right now

Whether your organization currently covers GLP-1 medications or not, your employees are taking them. According to recent survey data, roughly one in eight U.S. adults has now taken a GLP-1 medication. The utilization is happening, with or without your benefit plan's participation.

The strategic question for employers is not whether to engage with GLP-1 use. It's whether to engage with it on your terms, with clinical guardrails, behavioral support, and outcome accountability, or to absorb the costs of unmanaged access with no clinical or financial return.

In our next post: what a structured GLP-1 management program looks like, what outcomes the research supports, and how precision medicine approaches, matching treatment to individual patient biology, are changing the economics of obesity care.

Metriana is built on Mayo Clinic's precision medicine approach to weight management. Our platform combines phenotype-based treatment protocols with behavioral support designed to produce lasting outcomes, not short-term weight loss.